This article is more than 5 years old. Information may no longer be current.
Monotherapy shows promise in intraocular lymphoma
Click Here to Manage Email Alerts
Systemic therapy may prolong progression-free survival from primary intraocular lymphoma, according to a retrospective study.
While the optimal treatment for intraocular lymphoma has not been found, a systemic approach to therapy may prolong progression-free survival more than local management of the disease.
“The prognosis of primary intraocular lymphoma is similar to that of primary central nervous system lymphoma without ocular involvement,” the authors wrote.
For this study, researchers collected questionnaires from seven university ophthalmology departments on all non-HIV related cases of intraocular lymphoma over the past 5 years. The study included 22 patients, 19 of which had primary intraocular lymphoma and 3 with secondary intraocular lymphoma. Thirteen patients were treated with systemic chemotherapy, six patients were treated with ocular radiation, and three patients were treated with intraocular chemotherapy. Patients treated with ifosfamide or trofosfamide responded.
“The high response rate of monotherapy with [ifosfamide] and [trofosfamide] is promising,” the authors wrote.
Systemic therapy yielded a median progression-free survival of 12 months, and local first-line therapy yielded a median progression-free survival of 5.5 months, the authors said.
This study was published in the June issue of Graefe’s Archive for Clinical and Experimental Ophthalmology.